MesenFlow Technologies has developed a service platform to meet the demands of modern drug development. It has been designed to accelerate the development process and provide solutions to common problems associated with species cross-reactivity, animal testing and understanding human disease.
Products, services, technology
Multiple pharmaceutical and cosmetic companies have utilized MesenFlow in drug development campaigns. Our platform now includes more complex systems using a second tissue organoid culture chamber that enhances vascular cell behavior, leading to increased leukocyte recruitment under flow.
Cooperation possibilities
Our service is based on developing protocols that are designed to advance and complement existing client in-house activities. This has been achieved by constructing a bio-imaging microscope platform that measures the inflammatory mechanisms that define leukocyte accumulation in human tissue.
- http://mesenflow.com
- Send an email
- Paul Bradfield
Some insights
MesenFlow does not use animal experimentation and can be defined as a 3R technology. This was identified as a prevailing ethical consideration when MesenFlow was successfully adopted for use in cosmetics where animal testing is not permitted.
MesenFlow expects to contribute to SDG # 3 (one of the 17 Sustainable Development Goals established by the United Nations in 2015), by promoting good health and well-being, in helping their partners develop new drugs for human beings at a faster rate and lower cost.
We are committed to the development of drugs using translational techniques validated in University environments. We have built a platform that has enabled our partners to create new drug entities and practice 'quick-win fast-fail' strategies in an environment where attrition rates are very high.
They see a strong scientific ethic that meets the standard of peer-review, inventions that push boundaries in throughput, and elegance in finding simple solutions to difficult problems.
By facilitating meetings with like-minded entrepreneurs and inventors that share a passion for science and business development of out-the-box ideas.
Drug developers who are committed to developing a new generation of drugs using phenotypic screening, primary human cells and mechanism of action in the early discovery phase.